SecBot SecBot

GILD

GILEAD SCIENCES, INC.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0000882095 Biotech & Drug Discovery
$168.08 +0.13 (+0.08%)
Nov 13 4:00 PM ET · prev $167.95
Market cap
$208.3B
Mega cap
Consensus
Buy
83% Buy or better · 36 analysts
Median target
🔒 Subscribers only
1 year
+35.5%
from $124.09 · Nov 17
30 days
+9.8%
from $153.07
52-week range
$118.30–174.48
−4% from high · low Jan 5
Avg volume 20D
6.57M
shares / day
Short interest
21.27M
≈1.7% of shares · +4.9%
Days to cover
3.2
at average volume
Insider net
−$34.9M
since Aug 20 · excl. 4 subscriber-only trades
New fund stakes
4
Q3 2026 13F · 4 exits
Filing reports
30
analyzed by SecBot
SecBot read MIXED 18 reports · 90 days
Balance 1 bearish · 3 bullish · 14 neutral oldest → newest, height = score
Avg score ·High conf. 12/18 ·Next FDA decision date, Dec 23, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersMIXED

    6 insiders sold $34.9M. Excludes 4 subscriber-only trades.

  • InstitutionsMIXED

    Q3 2026: 51 added (4 new), 45 trimmed or exited. Largest new: Capital International Investors $228.5M, 1832 Asset Management $114.8M.

  • AnalystsBULLISH

    30 of 36 rate it Buy or better.

  • Short sellersSTEADY

    Short interest +4.9% to 21.27M shares. 3.2 days to cover, ≈1.7% of shares.

  • TrendUPTREND

    8% above its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 30.

Who's buying

13F· Q3 2026
4
new positions
4
exits
$373.9M
in new stakes · top 3 shown
FundMoveSharesValue
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ADD11,461,347$1.8B
DEUTSCHE BANK AG\ADD9,613,980$1.4B
UBS Group AGTRIM3,263,857$486.5M
BARCLAYS PLCTRIM3,141,208$468.2M
Swedbank ABADD2,875,154$428.5M
Assenagon Asset Management S.A.TRIM1,560,454$232.6M
Capital International InvestorsNEW1,532,767$228.5M
ProShare Advisors LLCTRIM1,444,047$215.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

36 analysts
Buy 83% rate it Buy or better
Strong Buy9Buy21Hold6Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 16, 2026🔒 Fresh data, subscribers only
MAINTAIN
MAINTAIN
Oct 30, 2026UBS
MAINTAIN
MAINTAINBuy
Oct 30, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Oct 30, 2026Citigroup
MAINTAIN
MAINTAINBuy
Oct 30, 2026Scotiabank
MAINTAIN
MAINTAINSector Outperform
Oct 30, 2026TD Cowen
MAINTAIN
MAINTAINBuy

Washington

Corporate Lobbying

109 lobbying filings and 6 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
bought · 0 insiders
$34.9M
sold · 6 insiders · excl. 4 subscriber-only trades
DateInsiderTypeValue
Nov 12, 2026🔒 Fresh data, subscribers only
Nov 12, 2026
SELL
Nov 12, 2026🔒 Fresh data, subscribers only
Nov 12, 2026
EXERCISE
Nov 12, 2026🔒 Fresh data, subscribers only
Nov 12, 2026
SELL
Nov 12, 2026🔒 Fresh data, subscribers only
Nov 12, 2026
SELL
Nov 12, 2026🔒 Fresh data, subscribers only
Nov 12, 2026
SELL
Nov 6, 2026
Cain Wettan Keeley M
EVP Gen Counsel, Legal & Comp
Nov 6, 2026
SELL$557.8K
Nov 5, 2026
O'Day Daniel Patrick
Chairman & CEO
Nov 5, 2026
SELL$1.7M
Nov 5, 2026
O'Day Daniel Patrick
Chairman & CEO
Nov 5, 2026
EXERCISE$709.7K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 15, 2026 Clinical trial readout
T-90d Trial Readout: Sacituzumab Govitecan-hziy (Phase 3)
Trial: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice
Nov 13, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 13, 2026 Event
🔒 Fresh data, subscribers only
Nov 12, 2026 Insider
🔒 Fresh data, subscribers only
Nov 12, 2026 Insider
🔒 Fresh data, subscribers only
Nov 12, 2026 Insider
🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
21,271,970
shares short
+4.9%
vs prior settlement
3.2
days to cover
≈1.7%
of shares outstanding
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
10 drugs tracked · Drug pipeline →
Upcoming
Recent
Congressional trades
GILD trades disclosed by members of Congress, with disclosure delay.
4 members · 8 buys / 3 sells
DateMemberType AmountDisclosed
Aug 10, 2026 Ro KhannaDHouse Child account · Gilead Sciences Inc SELL $1K–$15K Sep 4, 2026 +25d
Jul 20, 2026 Ro KhannaDHouse Spouse account · Gilead Sciences Inc BUY $1K–$15K Aug 7, 2026 +18d
Jul 7, 2026 Ro KhannaDHouse Child account · Gilead Sciences Inc SELL $1K–$15K Aug 7, 2026 +31d
May 15, 2026 Ro KhannaDHouse Spouse account · Gilead Sciences Inc BUY $15K–$50K Jun 9, 2026 +25d
May 6, 2026 Jared MoskowitzDHouse Gilead Sciences Inc BUY $1K–$15K Jun 19, 2026 +44d
May 6, 2026 Jared MoskowitzDHouse Child account · Gilead Sciences Inc BUY $1K–$15K Jun 19, 2026 +44d
Jan 27, 2026 Joshua GottheimerDHouse Joint account · Gilead Sciences Inc BUY $1K–$15K Feb 26, 2026 +30d
May 10, 2024 Tommy TubervilleRSenate Joint account · Gilead Sciences Inc BUY $1K–$15K Aug 5, 2026 +817d
May 10, 2024 Tommy TubervilleRSenate Joint account · Gilead Sciences Inc BUY $1K–$15K Aug 5, 2026 +817d
May 10, 2024 Tommy TubervilleRSenate Joint account · Gilead Sciences Inc BUY $1K–$15K Aug 5, 2026 +817d

SecBot reports

30 filings · 6 bullish · 3 bearish · 21 neutral
All GILD filing & press-release reports (30)